There is a growing interest in epigenetic drug development for investigational and therapeutic purposes.26, 27 Given the emergence of the oncogene EZH2 from our RNA sequencing data set, we focused on the role of this HMT in TGF-β–induced HSC activation and liver fibrosis in vivo. This evidence concerns the gene TGFB1 and Hepatic fibrosis.